Literature DB >> 1911851

A principal neutralizing domain of human immunodeficiency virus type 1 interacts with proteinase-like molecule(s) at the surface of Molt-4 clone 8 cells.

T Murakami1, T Hattori, K Takatsuki.   

Abstract

A principal neutralizing domain (PND) of the major envelope glycoprotein (gp120) of the HTLV-III BH10 strain of human immunodeficiency virus type 1 (HIV-1) has significant amino acid similarities to a reactive site of Kunitz-type basic proteinase inhibitors. We therefore thought that the PND may interact with cellular proteinase-like molecule(s) upon HIV-1 infection and measured the cellular proteolytic activities at the surface of intact Molt-4 clone 8 cells, which are highly susceptible to HIV-1 infection. The cells preferentially cleaved succinyl-Leu-Leu-Val-Tyr-4-methylcoumaryl-7-amide, a good substrate of chymotrypsin, and the activity was strongly inhibited by N-tosyl-L-phenylalanyl chloromethyl ketone (IC50 = 11.5 microM) and chymostatin (IC50 = 4.8 microM). A synthetic peptide of 24 residues (amino acids 308-331) that correspond to the PND also inhibited the cellular proteolytic activity in a dose-dependent manner (IC50 = 79.2 microM). The inhibition was still observed at low temperature (IC50 = 42.7 microM) and even after the peptide-treated cells were washed. We therefore think that the peptide interacts with proteinase-like molecule(s) located at the surface of the cells. The synthetic peptides from four other strains of HIV-1 corresponding to the PND similarly inhibited the proteolytic activity. These results may be helpful to clarify the novel mechanism(s) for HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911851     DOI: 10.1016/0167-4838(91)90070-g

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages.

Authors:  M A Handley; R T Steigbigel; S A Morrison
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.

Authors:  E A Berger; J R Sisler; P L Earl
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

3.  Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.

Authors:  P N Nehete; R B Arlinghaus; K J Sastry
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

Review 4.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

5.  Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.

Authors:  N Yahi; J Fantini; K Mabrouk; C Tamalet; P de Micco; J van Rietschoten; H Rochat; J M Sabatier
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4.

Authors:  A Werner; J A Levy
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

7.  Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.

Authors:  N Yahi; J M Sabatier; S Baghdiguian; F Gonzalez-Scarano; J Fantini
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.